Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Direct oral anticoagulants (DOACs) offer alternatives to warfarin for anticoagulation.
• Dose-reduced DOAC regimens serve distinct clinical purposes: dose-adjusted for full-intensity anticoagulation and low-intensity for extended durations.
• Understanding the evidence base and regulatory landscape for these reduced-dose regimens is crucial for optimal patient care.

Purpose of the Study:

• To review randomized clinical trials (RCTs) evaluating dose-adjusted and low-intensity DOACs.
• To compare findings from RCTs with labeled indications from regulatory authorities.
• To assess the alignment of real-world DOAC use, based on registry data, with established evidence and guidelines.

Main Methods:

• Systematic review of randomized clinical trials (RCTs) involving dose-reduced DOACs.
• Analysis of labeled indications for dabigatran, apixaban, rivaroxaban, and edoxaban across different regulatory authorities.
• Examination of large registry data to evaluate the concordance between clinical practice and trial findings.

Main Results:

• 35 RCTs investigated dose-adjusted DOACs, primarily for atrial fibrillation (AF) stroke prevention, showing efficacy and safety comparable to full-dose regimens.
• Low-intensity DOACs were studied in 37 RCTs for various indications including extended venous thromboembolism (VTE) treatment and primary prevention in specific patient groups.
• Registry data indicated instances where dose-reduced DOACs were used in ways not fully supported by RCTs or regulatory approvals, highlighting potential practice variations.

Conclusions:

• Dose adjustment of DOACs is primarily relevant for AF stroke prevention and should adhere to approved criteria; it is generally not recommended for acute VTE treatment.
• Low-intensity DOACs have established roles in VTE prevention for specific studied and approved indications.
• Clinical practice patterns for dose-reduced DOACs require careful monitoring to ensure alignment with evidence-based safety and efficacy data.